Holen Sie sich die Stockscreener-App
13.22
4.09%
0.52
Schlusskurs vom Vortag:
$12.70
Offen:
$12.7
24-Stunden-Volumen:
1.36M
Relative Volume:
0.80
Marktkapitalisierung:
$1.48B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-9.4429
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
+11.94%
1M Leistung:
+17.30%
6M Leistung:
-28.07%
1J Leistung:
-55.52%
1-Tages-Spanne:
$12.62
$13.25
1-Wochen-Bereich:
$11.36
$13.25
52-Wochen-Spanne:
$10.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.22 | 1.42B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
122.55 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.70 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.77 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.92 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st
Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Price Up 7%Time to Buy? - MarketBeat
What is the fair value estimate for NovoCure Limited (038) stock in 2025Weekly Trade Report & Verified Stock Trade Ideas - Newser
Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025? - Yahoo Finance
NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc. - MarketBeat
NovoCure stock rating reiterated at Buy by H.C. Wainwright amid CEO change - Investing.com Nigeria
NovoCure (NASDAQ:NVCR) Shares Gap DownShould You Sell? - MarketBeat
Can NovoCure's Tumor Treating Fields Redefine Cancer Care By 2026? - RTTNews
Novocure names Frank Leonard as new CEO, replacing Ashley Cordova By Investing.com - Investing.com Australia
How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm - simplywall.st
Novocure CEO Ashley Cordova resigns, Frank Leonard succeeds - TipRanks
Novocure (NVCR) Appoints New CEO Amid Leadership Change - GuruFocus
Novocure Ltd Announces CEO Transition - TradingView
Novocure (NASDAQ: NVCR) elevates President Frank Leonard to CEO as Ashley Cordova resigns - Stock Titan
Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Novocure (NASDAQ: NVCR) to Present at 37th Piper Sandler Healthcare Conference on Dec. 2 - Stock Titan
NovoCure Limited (NVCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will NovoCure Limited stock attract more institutional investorsInsider Buying & Breakout Confirmation Trade Signals - newser.com
Novocure at Jefferies London: Expanding Horizons in Cancer Treatment By Investing.com - Investing.com South Africa
Tangible book value per share of NovoCure Ltd. – DUS:038 - TradingView
Published on: 2025-11-19 05:31:32 - newser.com
Will NovoCure Limited stock benefit from green energy trendsPrice Action & AI Forecasted Entry/Exit Points - newser.com
NovoCure Limited (NVCR) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Using flow based indicators on NovoCure LimitedTrade Performance Summary & Safe Entry Zone Identification - newser.com
Why NovoCure Limited (038) stock could rally strongly2025 Analyst Calls & Weekly Watchlist of Top Performers - newser.com
How interest rate cuts could boost NovoCure Limited stockWeekly Gains Summary & Verified Entry Point Signals - newser.com
What sentiment indicators say about NovoCure Limited stockMarket Risk Report & Verified Short-Term Plans - newser.com
Can NovoCure Limited stock deliver sustainable ROEEarnings Beat & Risk Managed Investment Entry Signals - newser.com
NovoCure (NVCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Published on: 2025-11-14 04:19:47 - newser.com
Should Rising Losses Despite Higher Sales Require Action From NovoCure (NVCR) Investors? - simplywall.st
NVCR (NovoCure) ROA % : -11.44% (As of Sep. 2025) - GuruFocus
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - Yahoo Finance
Novocure (NASDAQ: NVCR) at Jefferies Healthcare, 2:00 p.m. GMT; webcast, 14-day replay - Stock Titan
NovoCure (NVCR): Assessing Valuation Following Q3 Sales Growth and Rising Net Losses - simplywall.st
Novocure stock hits 52-week low at 10.82 USD By Investing.com - Investing.com Australia
Novocure stock hits 52-week low at 10.82 USD - Investing.com
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):